BIIB

Biogen Inc. (NASDAQ: BIIB) is an American multinational biotechnology company that develops therapies for neurological diseases, neurodegenerative disorders, and rare genetic conditions. Headquartered in Cambridge, Massachusetts, Biogen is one of the largest independent biotechnology firms by market capitalization and maintains a global research and commercial presence.

Biogen traces its lineage to the 1970s; it merged with Idec Pharmaceuticals in 2003 to form Biogen Idec, and rebranded as Biogen in 2015. Its portfolio includes disease-modifying therapies for multiple sclerosis such as Avonex (interferon beta-1a) and Plegridy, as well as Tysabri (natalizumab), which Biogen co-developed with Elan. Spinraza (nusinersen), for spinal muscular atrophy, is marketed in collaboration with Ionis Pharmaceuticals. The company has expanded through acquisitions, including Bioverativ (hemophilia and related diseases) in 2018 and Nightstar Therapeutics in 2019.

In the 2020s Biogen pursued a broader central nervous system pipeline, including gene therapy and antisense approaches. In 2021 Biogen and Eisai obtained FDA approval for Aduhelm (aducanumab) for Alzheimer’s disease, a decision that generated substantial debate over efficacy, safety, and cost and has influenced regulatory and market considerations for the program. Biogen continues to operate globally, invests in research and development, and seeks partnerships to advance neuroscience-focused medicines.